Dashboard
1
High Management Efficiency with a high ROE of 24.76%
2
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 24.76%
3
Healthy long term growth as Operating profit has grown by an annual rate 51.85%
4
Flat results in May 25
5
With ROE of 20.73%, it has a expensive valuation with a 1.34 Price to Book Value
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 4,017 Million (Micro Cap)
6.00
NA
0.00%
-0.43
17.05%
1.37
Revenue and Profits:
Net Sales:
1,763 Million
(Quarterly Results - May 2025)
Net Profit:
122 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.23%
0%
-1.23%
6 Months
4.27%
0%
4.27%
1 Year
-17.18%
0%
-17.18%
2 Years
-41.41%
0%
-41.41%
3 Years
17.18%
0%
17.18%
4 Years
-13.53%
0%
-13.53%
5 Years
-12.6%
0%
-12.6%
Kowa Co. Ltd. (Osaka) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.32%
EBIT Growth (5y)
51.85%
EBIT to Interest (avg)
31.37
Debt to EBITDA (avg)
0.12
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
1.92
Tax Ratio
35.53%
Dividend Payout Ratio
8.28%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
33.78%
ROE (avg)
24.76%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
1.34
EV to EBIT
3.27
EV to EBITDA
2.55
EV to Capital Employed
1.61
EV to Sales
0.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
49.13%
ROE (Latest)
20.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - May'25 - QoQ
May'25
Nov'24
Change(%)
Net Sales
1,763.00
1,570.40
12.26%
Operating Profit (PBDIT) excl Other Income
260.90
247.20
5.54%
Interest
4.60
3.60
27.78%
Exceptional Items
1.10
2.40
-54.17%
Consolidate Net Profit
121.60
89.40
36.02%
Operating Profit Margin (Excl OI)
90.90%
113.10%
-2.22%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Feb'25
Feb'25
Feb'24
Change(%)
Net Sales
6,368.50
6,404.00
-0.55%
Operating Profit (PBDIT) excl Other Income
1,024.30
1,164.60
-12.05%
Interest
15.70
20.20
-22.28%
Exceptional Items
43.00
-36.40
218.13%
Consolidate Net Profit
633.70
723.00
-12.35%
Operating Profit Margin (Excl OI)
125.20%
148.10%
-2.29%
USD in Million.
Net Sales
YoY Growth in year ended Feb 2025 is -0.55% vs 2.16% in Feb 2024
Consolidated Net Profit
YoY Growth in year ended Feb 2025 is -12.35% vs 63.17% in Feb 2024
About Kowa Co. Ltd. (Osaka) 
Kowa Co. Ltd. (Osaka)
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






